Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Citi
UBS
Accenture
Argus Health

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 5,356,804

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,356,804
Title: Cloning and expression of biologically active human .alpha.-galactosidase A
Abstract:The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described. Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used in the treatment in Fabry Disease; for the hydrolysis of .alpha.-galactosyl residues in glycoconjugates; and/or for the conversion of the blood group B antigen on erythrocytes to the blood group O antigen.
Inventor(s): Desnick; Robert J. (New York, NY), Bishop; David F. (New York, NY), Ioannou; Yiannis A. (New York, NY)
Assignee: Mount Sinai School of Medicine of the City of New York (New York, NY)
Application Number:07/602,824
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,356,804
Patent Claims:see list of patent claims

Details for Patent 5,356,804

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24 ➤ Sign Up Mount Sinai School of Medicine of the City of New York (New York, NY) 2036-04-30 RX Orphan company
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 002 2003-04-24 ➤ Sign Up Mount Sinai School of Medicine of the City of New York (New York, NY) 2036-04-30 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Army
Express Scripts
McKesson
McKinsey
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.